Update: Enstilar – new psoriasis drug
In Clinical
Follow this topic
Bookmark
Record learning outcomes
Enstilar (calcipotriol and betamethasone dipropionate) is a new topical, alcohol-free, foam spray for all severities of plaque psoriasis in adults.
Manufacturer Leo says that “more than half of patients in clinical trials [experience] significant visible signs of improvement within four weeks with some patients seeing improvements at one weekâ€. In addition, 81 per cent of psoriasis patients using Enstilar foam spray reported improved quality of life after four weeks. More than 70 per cent reported reductions in itch-related
sleep loss.
“The symptomatic relief experienced by the majority of patients may be attributed to the cooling effect of the new foam spray,†Leo says.